<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04400890</url>
  </required_header>
  <id_info>
    <org_study_id>McCreary2020</org_study_id>
    <nct_id>NCT04400890</nct_id>
  </id_info>
  <brief_title>Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol for COVID-19</brief_title>
  <official_title>Randomized Double-Blind Placebo-Controlled Proof-of-Concept Trial of Resveratrol for the Outpatient Treatment of Mild Coronavirus Disease (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marvin McCreary, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mount Carmel Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is evidence that resveratrol might help fight coronavirus as well as help protect the
      body from the effects of disease (COVID-19) caused by the infection. In this proof-of-concept
      pilot study we will compare the effects of resveratrol to placebo to assess the safety of
      resveratrol and explore effectiveness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      200 subjects (100 receiving resveratrol, 100 receiving placebo) will be enrolled in study to
      compare whether taking resveratrol will reduce the rate of hospitalization. Subjects will
      take the treatment 4 times a day for 15 days, plus both groups will receive Vitamin D3
      100,000 IU to augment the effects of resveratrol.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization rates for COVID-19</measure>
    <time_frame>21 days from testing positive from COVID-19</time_frame>
    <description>Proportion of study participants admitted to the hospital within 21 days of testing positive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Admission Rates</measure>
    <time_frame>21 days from testing positive from COVID-19</time_frame>
    <description>Proportion of study participants admitted to the ICU within 21 days of testing positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive Ventilation Rates</measure>
    <time_frame>21 days from testing positive from COVID-19</time_frame>
    <description>Proportion of study participants receiving invasive ventilation within 21 days of testing positive</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reported symptom severity</measure>
    <time_frame>21 days from testing positive from COVID-19</time_frame>
    <description>Modified BORG scale, visual analog scale for fatigue</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>21 days from testing positive from COVID-19</time_frame>
    <description>Diarrhea, nausea, abdominal cramping</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Resveratrol with Vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Resveratrol for 15 days. Vitamin D3 100,000 IU on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with Vitamin D3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 15 days. Vitamin D3 100,000 IU on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Resveratrol vs placebo given for 15 days.</description>
    <arm_group_label>Resveratrol with Vitamin D3</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 100,000 IU given on day one.</description>
    <arm_group_label>Placebo with Vitamin D3</arm_group_label>
    <arm_group_label>Resveratrol with Vitamin D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients presenting to a Mount Carmel Health System (MCHS) Emergency Department
             (ED) or drive-through COVID-19 testing station, the Enhanced Urgent Care center in
             Hilliard (EUC), or other ambulatory MCHS facility who test positive for infection with
             SARS-CoV-2.

          -  Age ≥45 years

          -  Mild COVID-19 based on WHO Baseline Severity Categorization

          -  Symptom duration ≤ 7 days

          -  Patient must have access to the internet or a smartphone to complete surveys

          -  English-speaking patients

        Exclusion Criteria:

          -  Diagnosed or suspected cognitive impairment that would prevent the patient from
             cooperating with study procedures, as judged by the screening clinician

          -  Asymptomatic patients (e.g. patients who were screened without symptoms but tested
             positive)

          -  End stage liver disease or Hepatitis C

          -  Patients on warfarin, Novel Oral Anticoagulants (NOACs), HIV Protease Inhibitors,
             immunosuppressants, hydroxychloroquine/chloroquine

          -  Allergy to grapes or rice.

          -  Co-morbidities with a high likelihood of hospitalization within 30 days (e.g., current
             cancer treatment, severe COPD or CHF)

          -  Currently pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marvin R McCreary</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Carmel Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marvin R McCreary</last_name>
    <phone>(614) 526-8432</phone>
    <email>supplement4covid19@gmail.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mount Carmel Health System</investigator_affiliation>
    <investigator_full_name>Marvin McCreary, MD</investigator_full_name>
    <investigator_title>Emergency Physician</investigator_title>
  </responsible_party>
  <keyword>Coronavirus</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID</keyword>
  <keyword>Resveratrol</keyword>
  <keyword>Stilbene</keyword>
  <keyword>Vitamin D3</keyword>
  <keyword>Cholecalciferol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

